Top

Published in:

01-05-2020 | NSCLC | Original Article

EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer

Authors: Yukitoshi Satoh, Yukiko Matsuo, Tatsuru Kuba, Kazuya Yamashita, Mariko Sawano, Shusaku Tozaka, Hirotsugu Yamazaki, Dai Sonoda, Masashi Mikubo, Masahito Naito, Yoshio Matsui, Kazu Shiomi, Tsutomu Yoshida, Yoshiki Murakumo

Published in: Virchows Archiv | Issue 5/2020

Abstract

Personalised medicine for primary lung cancers (PLCs) requires molecular analysis of cancer tissue or cells. The primary objective of the present prospective study was to assess the concordance between epidermal growth factor receptor (EGFR) gene mutation detection and echinoderm microtubule-associated protein-like (EML) 4-anaplastic lymphoma kinase protein (ALK) expression using liquid-based cytology (LBC) samples and matched histology samples of PLC patients. A total of 117 patients who underwent surgical resection of non-small cell PLC were enrolled. Cytological specimens scratched from the resected PLC lesion were fixed in CytoRich Red. DNA extracted from LBC samples was examined for EGFR gene mutations. Anaplastic lymphoma kinase arrangement was analysed by immunostaining and fluorescence in situ hybridisation. Our patient cohort comprised 93 cases of adenocarcinoma, 16 squamous cell carcinoma, three adenosquamous carcinoma, two large cell neuroendocrine carcinoma, one pleomorphic carcinoma and two other cases. Sixty-six (58.4%) LBC samples harboured EGFR gene mutations. The overall concordance rate in EGFR gene mutation status, including minor mutations, between histologic and paired LBC specimens (N = 105) was 100%. The overall concordance rate of EGFR gene mutation status, including minor mutations and ALK status according to immunostains between histologic and paired LBC specimens, was 100% (105/105) and 100% (48/48), respectively. Genotyping and protein expression studies can be reliably performed using LBC samples prepared with CytoRich Red. Analysis of such samples may guide individual therapy in PLC patients.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:730. https://doi.org/10.3322/caac.21442 CrossRef

van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379CrossRef

Masuda M, Endo S, Natsugoe S, Shimizu H, Doki Y, Hirata Y et al (2018) Thoracic and cardiovascular surgery in Japan during 2015. Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 66:581–615CrossRef

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D et al (2010) European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5:1706–1713. https://doi.org/10.1097/JTO.0b013e3181f1c8de. CrossRefPubMed

Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, Ivantsov AO, Togo AV, Polyakov IS, Orlov SV, Matsko DE, Novik VI, Imyanitov EN (2013) Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 121:370–376CrossRef

National Comprehensive Cancer Network. Non-small cell lung cancer (version 5.2018). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM et al (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121–2127. https://doi.org/10.1200/JCO.2010.31.8923 CrossRefPubMed

Reynolds JP, Tubbs RR, Minca EC, MacNamara S, Almeida FA, Ma PC, Pennell NA, Cicenia JC (2014) EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non–small cell lung cancer (NSCLC). Lung Cancer 86:158–163. https://doi.org/10.1016/j.lungcan.2014.09.003 CrossRefPubMed

Kawahara A, Fukumitsu C, Taira T, Abe H, Takase Y, Murata K, Yamaguchi T, Azuma K, Ishii H, Takamori S, Akiba J, Hoshino T, Kage M (2015) Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings. Cancer Cytopathol 123:620–628. https://doi.org/10.1002/cncy.21583 CrossRefPubMed

10.

van Eijk R, Licht J, Schrumpf M, Talebian Yazdi M, Ruano D, Forte GI, Nederlof PM, Veselic M, Rabe KF, Annema JT, Smit V, Morreau H, van Wezel T (2011) Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non–small-cell lung cancer using allele-specific qPCR. PLoS One 6:e17791. https://doi.org/10.1371/journal.pone.0017791 CrossRefPubMedPubMedCentral

11.

Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, Munavvar M, Ng BJ, Rassl DM, Falzon M, Kocjan G, Rintoul RC, Nicholson AG, Janes SM (2012) Suitability of endobronchial ultrasound–guided transbronchial needle aspiration specimens for subtyping and genotyping of non–small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 185:1316–1322CrossRef

12.

Santis G, Angell R, Nickless G, Quinn A, Herbert A, Cane P, Spicer J, Breen R, McLean E, Tobal K (2011) Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non–small cell lung cancer using COLDPCR. PLoS One 6:e25191. https://doi.org/10.1371/journal.pone.0025191 CrossRefPubMedPubMedCentral

13.

Malapelle U, de Rosa N, Bellevicine C, Rocco D, Vitiello F, Piantedosi FV, Illiano A, Nappi O, Troncone G (2012) EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol 65:561–564. https://doi.org/10.1136/jclinpath-2011-200659 CrossRefPubMed

14.

Minca EC, Lanigan CP, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR (2014) ALK status testing in non–small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol 9:464–468. https://doi.org/10.1097/JTO.0000000000000104 CrossRefPubMed

15.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P (2013) Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol 121:500–507. https://doi.org/10.1002/cncy.21288 CrossRefPubMed

16.

Zhao H, Qiu T, Guo H, Ying J, Li J, Zhang Z (2017) Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma. Oncotarget 8:106685–106692. https://doi.org/10.18632/oncotarget.22530. CrossRefPubMedPubMedCentral

17.

Magnini D, Fuso L, Varone F, D'Argento E, Martini M, Pecoriello A, di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L (2018) Molecular testing in EBUS-TBNA specimens of lung adenocarcinoma: a study of concordance between cell block method and liquid-based cytology in appraising sample cellularity and EGFR mutations. Mol Diagn Ther 22:723–728. https://doi.org/10.1007/s40291-018-0359-3 CrossRefPubMed

18.

Reynolds JP, Zhou Y, Jakubowski MA, Wang Z, Brainard JA, Klein RD, Farver CF, Almeida FA, Cheng YW (2017) Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples. Cancer Cytopathol 125:178–187. https://doi.org/10.1002/cncy.21812 CrossRefPubMed

19.

Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR, Hoeltge GA, Leonard DG, Merker JD, Nagarajan R, Palicki LA, Robetorye RS, Schrijver I, Weck KE, Voelkerding KV (2015) College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 139:481–493. https://doi.org/10.5858/arpa.2014-0250-CP CrossRefPubMed

20.

Wallace WA, Monaghan HM, Salter DM, Gibbons MA, Skwarski KM (2007) Endobronchial ultrasound-guided fine-needle aspiration and liquid-based thin-layer cytology. J Clin Pathol 60:388–391. https://doi.org/10.1136/jcp.2006.038901 CrossRefPubMed

21.

Wu GP, Wang EH, Li JH, Fu ZM, Han S (2009) Clinical application of the liquid-based cytological test in cytological screening of sputum for the diagnosis of lung cancer. Respirology. 14:124–128. https://doi.org/10.1111/j.1440-1843.2008.01399.x CrossRefPubMed

22.

Hansen T, Pedersen H, Brauner V, Hariri J (2011) Control specimens for immunocytochemistry in liquid-based cytology. Cytopathology 22:243–246. https://doi.org/10.1111/j.1365-2303.2010.00755.x CrossRefPubMed

23.

Doxtader EE, Cheng YW, Zhang Y (2019) Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration. Arch Pathol Lab Med 143:670–676. https://doi.org/10.5858/arpa.2017-0184-RA CrossRefPubMed

24.

Wu CY, Hou LK, Ren SX, Su B, Chen G (2014) High feasibility of liquid-based cytological samples for detection of EGFR mutations in Chinese patients with NSCLC. Asian Pac J Cancer Prev 15:7885–7889. https://doi.org/10.7314/apjcp.2014.15.18.7885 CrossRefPubMed

25.

Gleeson FC, Kipp BR, Levy MJ, Voss JS, Campion MB, Minot DM, Tu ZJ, Klee EW, Lazaridis KN, Kerr SE (2014) Lung cancer adrenal gland metastasis: optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. Cancer Cytopathol 122:822–832. https://doi.org/10.1002/cncy.21464 CrossRefPubMed

26.

Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L, IASLC Pathology Committee (2019) Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathol 127:325–339. https://doi.org/10.1002/cncy.22137 CrossRefPubMed

27.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 13:323–358. https://doi.org/10.1016/j.jtho.2017.12.001. CrossRefPubMed

Title: EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer
Authors: Yukitoshi Satoh
Yukiko Matsuo
Tatsuru Kuba
Kazuya Yamashita
Mariko Sawano
Shusaku Tozaka
Hirotsugu Yamazaki
Dai Sonoda
Masashi Mikubo
Masahito Naito
Yoshio Matsui
Kazu Shiomi
Tsutomu Yoshida
Yoshiki Murakumo
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Published in: Virchows Archiv / Issue 5/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02692-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas

Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis

The broad and challenging landscape of extranodal lymphoproliferations

Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1

Small-bowel carcinomas associated with celiac disease: transcriptomic profiling shows predominance of microsatellite instability-immune and mesenchymal subtypes

Lymphoproliferations at extranodal sites: a morphologically, genetically, and clinically diverse group of neoplasms with overlapping features